Abstract 487P
Background
The United States Preventive Services Task Force (USPSTF) recommends low dose CT screening for lung cancer in individuals (1) 50-80 years old, (2) currently smoking or had quit for less than 15 years and (3) had at least a 20 pack-year smoking history. It is unclear if these guidelines will be applicable to our mixed Asian population. Our aim is to evaluate the performance of the USPSTF lung cancer screening criteria in our population of lung cancer patients.
Methods
We retrospectively reviewed the records of all asymptomatic patients who underwent resection of primary lung cancer in our institution between 2019 and 2021. Data collected included demographics, smoking status, histology and the final staging.
Results
We reviewed 259 consecutive cases of resectable primary lung cancer patients between 2019 and 2021. 145 patients were males (56.0%) and 114 patients were females (44.0%). There were 123 (47.5%) active or former smokers and 136 (52.5%) non-smokers. 83 patients (32.0%) met the USPSTF screening criteria and 176 patients (68.0%) did not. Lowering the age criteria to 45 years old increased the pickup rate to 34.4%. Male patients were more likely to meet the criteria (OR 2.27, 95% CI 1.87-2.76, p < 0.001) than female patients. The pickup rate increased significantly to 40.5% when patients who had stopped smoking for more than 15 years were included (p < 0.001) and 44.4% (p < 0.001) when patients who smoked less than 20 pack years were included. Screening by age criteria alone resulted in a pickup rate of 93.8% (males 94.5%, females 93.0%). Within this age range, the pickup rate in females was 84.2% in non-smokers and 8.8% in active or former smokers whilst the pickup rate in male was 22.1% in non-smokers and 72.4% in active or former smokers.
Conclusions
Our study showed the performance of the USPSTF criteria when applied to a mixed Asian population. It is concerning that more than two-thirds of patients will miss the opportunity for early curative resection if the guidelines were followed. A significant proportion of our patients were non-smokers, especially in the female population. A lung screening programme will need to be refined from existing guidelines to fit our local mixed Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract